Securities code: 300142 securities abbreviation: Walvax Biotechnology Co.Ltd(300142) Announcement No.: 2022-008 Walvax Biotechnology Co.Ltd(300142)
About the subsidiary received the New Coronavirus variant vaccine (CHO cell) overseas clinical trial ethical approval and received CEPI funding announcement.
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Walvax Biotechnology Co.Ltd(300142) (hereinafter referred to as "company"), a subsidiary of Shanghai Ze run Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Ze run") has independently developed the recombinant New Coronavirus variant vaccine (CHO cell), which was approved by the ethics committee of Bamako University of science and technology in recent days, and approved by the ethics committee. It is agreed to carry out phase I / II clinical trial of the vaccine in Mali to evaluate the safety, reactivity and immunogenicity of the vaccine in healthy adults aged 18 to 60.
The recombinant New Coronavirus vaccine (CHO cell) developed by Shanghai Ze run is used to prevent diseases caused by SARS-CoV-2 infection. Shanghai Ze Ran has had a vaccine against New Coronavirus prototype in phase II clinical trials. The approved New Coronavirus vaccine approved for clinical trials is a vaccine against New Coronavirus variant strains. Recently, the European Drug Administration (EMA) has approved China's New Coronavirus research and development of New Coronavirus recombinant protein vaccine NVX-CoV2373 conditional listing, WHO (WHO), India, Indonesia, Philippines, Korea, Australia and other national drug regulatory departments have also approved the Novavax company's emergency use of the vaccine authorization, China Chongqing Zhifei Biological Products Co.Ltd(300122) , Sinopharm China biological recombinant protein covid-19 vaccine has also been authorized for emergency use. The recombinant protein vaccine targeting New Coronavirus variant is currently in the research stage.
Meanwhile, the epidemic prevention Innovation Alliance (CEPI) announced that it would provide us $8.15 million to Shanghai Zerun to support the phase I / II clinical trial to be carried out in Mali. Up to now, CEPI's financial support for covid-19 candidate vaccine of Shanghai Zerun has reached US $25.1 million.
With the increasing vaccination rate of covid-19 vaccine in the world and the continuous variation of covid-19 virus, the implementation of vaccine clinical trial faces many challenges. There are still some uncertainties in the progress and results of phase I / II clinical trial of this vaccine. In the follow-up, the company will timely perform the obligation of information disclosure in accordance with the provisions of relevant regulations and normative documents. The vaccine is approved to enter phase I / II clinical trials, which will increase the company's R & D investment. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Walvax Biotechnology Co.Ltd(300142) board of directors
February 9, 2002
